Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
Aditya BardiaSheng SunNayana ThimmiahJames T T CoatesBogang WuRachel Occhiogrosso AbelmanLaura M SpringBeverly MoyPhoebe RyanMark N MelkonyanAnn H PartridgeDejan JuricJeffrey M PeppercornHeather A ParsonsSeth A WanderVictoria AttayaBrenda LormilMaria ShellockAiko NagayamaVeerle BossuytSteven Jay IsakoffSara M TolaneyLeif W EllisenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
While SG dosed concurrently with TZP is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG followed by TZP proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.